This company has been marked as potentially delisted and may not be actively trading. TCR2 Therapeutics (TCRR) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock TCRR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Poseida Therapeutics Inc Ordinary Shares PSTXFebruary 25, 2024 | morningstar.comMDICE Therapeutics Inc.June 20, 2023 | wsj.comAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyJune 1, 2023 | finance.yahoo.comTCR2 Therapeutics (Nasdaq:TCRR) HeadlineTrading was temporarily halted for "TCRR" at 07:05 PM with a stated reason of "News pending."...June 1, 2023 | marketbeat.comTCR2 Therapeutics Insider Trades Send a SignalMay 16, 2023 | benzinga.comRecap: TCR2 Therapeutics Q1 EarningsMay 12, 2023 | msn.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | marketwatch.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite RiskyApril 15, 2023 | finance.yahoo.comMizuho Downgrades Tcr2 Therapeutics (TCRR)March 25, 2023 | msn.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho SecuritiesMarch 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)March 23, 2023 | markets.businessinsider.comTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finanznachrichten.deTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finance.yahoo.comWhat To Know About Jefferies's Downgrade of TCR2 TherapeuticsMarch 9, 2023 | msn.com4 Analysts Have This to Say About TCR2 TherapeuticsMarch 9, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. WainwrightMarch 8, 2023 | markets.businessinsider.comShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with AdaptimmuneMarch 6, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. BuyoutMarch 6, 2023 | benzinga.comWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?March 6, 2023 | investorplace.comTCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsMarch 6, 2023 | finanznachrichten.deAdaptimmune To Combine With TCR² In All-stock Deal - Quick FactsMarch 6, 2023 | markets.businessinsider.comAdaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsMarch 6, 2023 | finance.yahoo.comAdaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsMarch 6, 2023 | finance.yahoo.comTCR2 Therapeutics Stock (NASDAQ:TCRR), Quotes and News SummaryFebruary 16, 2023 | benzinga.comTCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023February 8, 2023 | finance.yahoo.comTCRR.C - | Stock Price & Latest News | ReutersJanuary 18, 2023 | reuters.comSVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)January 9, 2023 | markets.businessinsider.comTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 5, 2023 | finance.yahoo.comTCR² Therapeutics Announces Pipeline Priorities for 2023January 5, 2023 | finance.yahoo.comTCR2 Therapeutics Inc. (TCRR)January 2, 2023 | uk.finance.yahoo.comTCRR TCR2 Therapeutics Inc.December 16, 2022 | seekingalpha.comTCR² Therapeutics to Present at the Piper Sandler Healthcare ConferenceNovember 23, 2022 | finance.yahoo.comDown 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)November 11, 2022 | finance.yahoo.comTCR2 Therapeutics: TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 8, 2022 | finanznachrichten.deTCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 8, 2022 | finance.yahoo.comTCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of CancerNovember 7, 2022 | finance.yahoo.comIs TCR2 Therapeutics (NASDAQ:TCRR) In A Good Position To Deliver On Growth Plans?November 6, 2022 | finance.yahoo.comTCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, MesotheliomaSeptember 28, 2022 | finance.yahoo.comTCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trialSeptember 28, 2022 | seekingalpha.comgavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and MesotheliomaSeptember 28, 2022 | finance.yahoo.comTCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid TumorsSeptember 27, 2022 | finance.yahoo.comTCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitSeptember 26, 2022 | finance.yahoo.comTCR2 Therapeutics (NASDAQ:TCRR) Price Target Cut to $18.00August 23, 2022 | marketbeat.comTCR² Therapeutics: Betting On A Solid ReversalAugust 19, 2022 | seekingalpha.comRoth Capital Reaffirms Buy Rating for TCR2 Therapeutics (NASDAQ:TCRR)August 10, 2022 | marketbeat.comTCR2 Therapeutics (NASDAQ:TCRR) Posts Quarterly Earnings ResultsAugust 9, 2022 | marketbeat.comTCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 8, 2022 | finance.yahoo.comWhat Kind Of Shareholders Hold The Majority In TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) Shares?August 8, 2022 | finance.yahoo.comTCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Average Rating of "Moderate Buy" by BrokeragesAugust 8, 2022 | americanbankingnews.com Get TCR2 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRR Media Mentions By Week TCRR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TCRR News Sentiment▼0.001.09▲Average Medical News Sentiment TCRR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TCRR Articles This Week▼00▲TCRR Articles Average Week Get TCR2 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Inhibikase Therapeutics News Protalix BioTherapeutics News Invizyne Technologies News ZIVO Bioscience News CEL-SCI News Calidi Biotherapeutics News AlloVir News NKGen Biotech News Chromocell Therapeutics News AIM ImmunoTech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TCRR) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TCR2 Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TCR2 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
